Ninth Circuit Remands Royalty Dispute Over Zilactin

Law360, New York (September 5, 2007, 12:00 AM EDT) -- A federal appeals court has ruled that a lower court overstepped its bounds by determining that an agreement over royalties for a patent covering a herpes treatment was unenforceable.

The U.S. Court of Appeals for the Ninth Circuit on Wednesday found that the U.S. District Court for the District of Nevada wrongly applied a prior ruling by the Supreme Court to allow a patent holding company to stop making royalty payments to the inventor of the original patent of Zilactin, a liquid solution to treat herpes....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.